Mallinckrodt (MNK) wins IPR decisions on INOMax blood-vessel drug - Bloomberg
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Mallinckrodt (NYSE: MNK) wins IPR decisions on INOMax blood-vessel drug, according to Bloomberg.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mallinckrodt (MNK) Announces Court Affirmation to Stay Litigation Pending FDA’s Approval Withdrawal Proceedings Outcome
- Stocks with Implied Volatility Movement
- Concordia International (CXRX) Says It's Part of Inquiry by UK's CMA
Create E-mail Alert Related CategoriesLitigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!